BridgeBio Oncology
BBOT
31 hedge funds and large institutions have $186M invested in BridgeBio Oncology in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
8% more capital invested
Capital invested by funds: $173M → $186M (+$13.6M)
0.22% more ownership
Funds ownership: 86.97% → 87.19% (+0.22%)
3% less funds holding
Funds holding: 32 → 31 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
+$4.03M |
| 2 |
HCI
Harraden Circle Investments
New York
|
+$2.89M |
| 3 |
JP Morgan Chase
New York
|
+$1.64M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.08M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$5.25M |
| 2 |
SFM
Soros Fund Management
New York
|
-$3.49M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$2.63M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.36M |
| 5 |
PA
Perceptive Advisors
New York
|
-$1.1M |
BBOT Hedge Fund Activity: Q1 2025 in Review
31 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q1 2025, worth a combined $186M — up 7.9% from $173M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBOT and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 9 added.
The largest buyer was Fort Baker Capital Management, opening a new position worth an estimated $4.03M. The largest seller was Commodore Capital, exiting entirely with an estimated $5.25M sold.
- 31 institutional investors held BridgeBio Oncology (BBOT) as of Q1 2025, down from 32 in Q4 2024.
- Funds reported $186M of BridgeBio Oncology stock for Q1 2025, up 7.9% quarter-over-quarter.
- 3 funds opened new BridgeBio Oncology positions in Q1 2025 and 4 closed out, a net change of -1 holder.
- The largest BridgeBio Oncology buyer in Q1 2025 was Fort Baker Capital Management, an estimated $4.03M added.
- The largest BridgeBio Oncology seller in Q1 2025 was Commodore Capital, an estimated $5.25M sold.
Based on aggregated 13F filings for Q1 2025.